

# Index

## A

Accelerometer, 92  
Actigraphy, 97–100  
Acupuncture, 223, 245, 248, 437–440  
AD. *See* Atopic dermatitis (AD)  
Aetiology, 71, 76, 89, 90, 217, 284, 285, 313, 315, 316, 320, 379  
Allergic Contact Dermatitis, 132, 145–148, 408  
Allergy, 19, 151, 164, 332, 337, 360, 395  
Allodynia, 35, 43, 58, 71, 205, 225, 230, 231, 237, 379, 380, 383, 408  
Alloknesis, 35, 71, 220, 390  
Amphiregulin, 135  
Amyloidosis, 124–126, 219, 221, 238, 269, 319, 390  
Analgesics, 26, 27, 34, 37, 70, 72, 106–107, 238, 257, 359, 380, 384, 389  
Anamnesis, 85, 87, 88  
Anaphylaxis, 151, 162–164  
Anesthetics, 352, 360  
Angioedema, 151–154, 162, 163, 194, 201  
Anogenital pruritus, 58  
Anosmin-335, 135–136  
Antagonist, 16–17, 26, 34–35, 39, 70, 98, 106, 131, 137, 154, 155, 164, 170, 171, 173, 175, 186, 227, 245–247, 257, 258, 260–261, 275, 277, 286, 311, 317, 318, 347, 348, 352, 353, 359, 360, 365, 371, 372, 389–391, 399, 403, 407–412, 431, 438, 443  
Anticonvulsant medication, 227  
Anticonvulsants, 227, 231, 247, 347, 348, 379–386, 444  
Antidepressants, 71, 155, 169–170, 212, 217, 227, 231, 237–238, 276, 286, 347, 348, 393–395, 420, 431, 443  
Antihistamines, 16, 70, 88, 104, 131, 132, 137, 140, 147, 154, 155, 164, 171–174, 185, 193, 202–205, 211, 212, 222, 253, 274–277, 286, 317, 320, 325, 345, 346, 360, 363–372, 381, 384, 385, 391, 393, 410  
Anti-IgE, 193–194  
Antimalarials, 169–172, 323  
Antipruritics, 26–28, 37, 49, 51, 52, 97, 131–132, 138–140, 148, 171, 172, 174, 185, 186, 193, 222, 245–247, 257, 260, 261, 276–278, 286, 315, 345–349, 353, 359, 360, 371, 379, 380, 383–385, 390, 391, 393, 394, 397–403, 409, 411, 443, 444

Antipruritic therapy, 138–139, 345–347, 349, 397, 400, 402, 443  
Anxiety, 93, 106, 112, 119, 120, 175, 291, 296, 299, 302, 304, 311, 317, 318, 380, 384, 407, 415, 417, 418, 420  
Aprepitant, 137, 175, 227, 277, 286, 408–412  
Aquagenic, 88, 153, 172, 271–278, 296, 352, 371, 385, 428, 431–432  
Artemin, 135, 137  
Astrocytoma, 216  
Atopic dermatitis (AD), 79, 16, 25, 37, 39, 74, 82, 97, 104, 112, 124, 131, 152, 163, 186, 210, 245, 255, 275, 290, 296, 302, 310, 313, 330, 346, 352, 355, 360, 365, 379, 389, 394, 397, 416, 427–428, 439–440, 437  
ATX. *See* Autotaxin (ATX)  
Autoimmune diseases, 112, 189–195, 216  
Autotaxin (ATX), 17, 39, 42, 132, 257  
Axon guidance molecule, 137, 138

## B

Back, 58, 62, 87, 97, 98, 126, 145, 152, 172, 201, 219–221, 236, 241, 242, 255, 269, 298, 315, 324, 332, 411, 415, 417  
BB-UVB, 425–433  
Bile salt, 255–256, 258, 260, 431  
Biologics, 154, 169, 175, 185, 363, 384, 399, 402, 403  
BNP. *See* B-type natriuretic peptide (BNP)  
Brain, 335, 44, 6, 21–28, 31, 49, 70, 71, 103, 118, 119, 137, 184, 195, 215–217, 245, 261, 295, 297, 310, 365, 368  
Brain imaging, 6, 21, 23–25, 28  
B-type natriuretic peptide (BNP), 18, 33, 39, 137  
Bullous Pemphigoid, 124, 191–192, 322  
Burden, 74, 111, 113, 114, 152, 159, 160, 164, 241, 254, 289–292, 304, 310–311, 326, 444  
Burn, 55, 16, 24, 43, 62, 69, 71, 88, 113, 118, 120, 127, 128, 146, 152, 174, 190, 205, 210, 215, 220, 222, 225, 227, 229–231, 236, 254, 268, 272, 303, 315, 322–324, 329, 332, 334, 335, 337–339, 352, 356, 417, 428

**C**

Calamine, 360–361  
 Calcineurin, 138, 148, 169, 314, 317, 325, 346, 348, 355, 356  
 Calcitonin-gene-related peptide, 134  
 Calcium channel blockers, 169, 170, 247  
 Camphor, 359–361  
 Cancer, 42, 73, 75, 76, 162, 176, 261, 283–286, 297, 336, 384, 394, 398, 410, 433  
 Candidosis, 267, 329–332  
 Capsaicin, 18, 34, 36, 40, 50–52, 69, 71, 120, 174, 185, 222, 227, 231, 238, 273, 277, 351–353, 356, 408, 443  
 Capsaicin dermal patch, 231  
 Capsaicin patch, 227, 352, 353  
 Carcinoid, 162, 267, 269  
 CD121, 157, 162  
 Celiac disease, 238, 269, 322  
 Cell culture, 426  
 Central perception, 71, 118  
 Central sensitization, 39–44, 71, 225–226, 236, 310, 379, 380, 384, 386, 408  
 Chemokines, 79, 99, 132, 193, 210, 211  
 Children, 74, 95, 99, 100, 158, 159, 163, 164, 201, 205, 215, 243, 244, 260, 262, 298, 301, 313–326, 333–335, 345, 346, 360, 366, 384, 398, 399, 401, 402, 416, 419, 444  
 Chloroquine (CQ), 44, 16, 18, 134, 137, 148, 170–172, 253  
 Cholestasis, 75, 89, 171, 245, 253–262, 315, 390, 394, 395, 430, 431  
 Chronic itch, 55–79, 21, 24–26, 28, 35–37, 39, 40, 43, 44, 57, 58, 61, 70, 71, 73, 75–77, 81, 90, 107, 136, 137, 222, 241–243, 255, 257, 268, 274, 275, 284, 285, 290, 301–305, 310, 393–395, 397, 399, 422  
 Chronic kidney disease (CKD), 81, 124, 125, 241–248, 383, 385, 386, 391, 394, 399, 411, 443  
 Chronic pain, 55, 79, 26, 27, 40, 42, 43, 71, 118, 120, 172, 379  
 Chronic pruritus (CP), 25, 40–43, 57–63, 73–77, 81, 82, 85, 87, 90, 91, 93, 94, 97, 111–115, 117–120, 123, 131, 146, 147, 227, 236, 253–255, 262, 267, 271, 273, 278, 290, 295, 301–302, 308, 313, 326, 330, 345–349, 360, 372, 379–381, 386, 407–409, 411, 415, 416, 443, 444  
 Chronic scratch lesions, 82, 87, 94, 125, 225, 385  
 Chronic spontaneous urticaria, 151, 153–155, 318  
 Chronic urticaria, 151–155, 193–194, 200, 268, 271, 291, 297, 304, 317, 318, 322, 370, 371, 397, 400, 428  
 CKD. *See* Chronic kidney disease (CKD)  
 Classification, 81–83, 89, 123, 158–163, 209, 276, 285, 295–297, 308–309, 323, 336, 349, 379  
 Clinical examination, 85, 87–90, 120, 197, 236, 285, 322, 415  
 Clinical presentation, 57, 82, 85, 89, 123–126, 145, 158, 163, 198, 201, 210–212, 273, 284–285, 317, 319  
 Community, 13, 73, 74, 138, 202, 290, 348  
 Conditioning, 103–107, 303, 317, 355

Contact dermatitis, 44, 79, 124, 132, 139, 145–148, 205, 222, 330–332, 337, 408  
 Corneal confocal microscopy, 61  
 Cowhage, 335, 44, 14–16, 18, 23–25, 31, 35–37, 39–41, 50, 70, 360  
 CP. *See* Chronic pruritus (CP)  
 CQ. *See* chloroquine (CQ)  
 CTCL. *See* Cutaneous T-cells lymphoma (CTCL)  
 Cutaneous lymphoma, 209–213, 277, 390, 429, 433  
 Cutaneous T-cells lymphoma (CTCL), 276, 402, 409–410, 429–430  
 Cyclosporine, 140, 148, 164, 244, 348, 397–398  
 Cytokine receptor, 15, 17  
 Cytokines, 79, 14, 15, 17, 131, 139, 147, 151–153, 157, 164, 170, 175, 184, 185, 193, 210, 211, 237, 244, 268, 269, 274, 275, 283, 316, 319, 363, 364, 397, 399–403, 426, 427, 431, 443

**D**

Depression, 71, 93, 97, 112, 119, 120, 128, 162, 164, 184, 194, 260, 262, 290–291, 296, 302, 307, 311, 389, 395, 407, 409, 412, 415, 417, 420, 444  
 Dermatitis herpetiformis duhring, 192  
 Dermatologic pruritus, 75, 76, 89, 195, 255  
 Dermatology, 27, 28, 73, 76, 93, 111, 152, 190, 220, 271, 289, 290, 295, 301, 303, 308, 348, 351, 359, 416, 419, 420, 437  
 Dermatomyositis, 124, 189–190, 284, 285  
 Dermatophagoides farinae body (Dfb), 136–139  
 Dermatoses, 74–76, 82, 87, 89, 91, 93, 112, 123, 124, 152, 198, 210, 212, 222, 226, 229, 284, 285, 295, 297, 302, 313–317, 322–324, 326, 345–347, 355, 360, 418  
 Dermatitis, 75, 87, 91, 94, 124, 126, 193, 197, 199, 226, 273, 278, 301, 316, 322–323, 331, 335–338, 363, 370, 372, 415, 416, 444  
 Desire to scratch, 21, 23, 25, 26, 97, 131, 295  
 Diabetes, 61, 75, 77, 226, 236, 238, 268, 332, 351  
 Diabetes mellitus, 61, 63, 77, 87, 226, 242, 267–268  
 Diagnosis, 57, 60, 61, 76, 85, 87, 89, 112, 114, 119, 146, 153, 154, 158, 161, 162, 190, 192, 198–201, 203–205, 209, 210, 215, 219–222, 230, 236, 241, 242, 269, 272–274, 284, 285, 295–297, 304, 307–311, 315, 319–321, 324, 329–335, 337, 339  
 Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 309  
 Diagnostics, 58, 60–61, 76, 81, 82, 85, 88, 90, 91, 111, 114, 137, 153, 154, 159, 161, 163, 197, 226, 230, 231, 236–237, 283–285, 303, 307–309, 311, 316, 321, 331, 337, 345, 346, 348, 394  
 Dialysis, 25, 76, 83, 241–247, 258, 302, 431  
 Diseased/normal skin, 59, 82, 87, 89, 123, 134, 163, 201, 202, 408  
 Doctor-patient communication, 105, 106  
 Dorsal root ganglion (DRG), 55, 18, 40, 50, 60, 131, 132, 134–136, 138, 140, 212, 237, 256, 268, 356, 380, 383  
 Doxepin, 155, 286, 311, 360, 394, 395  
 DRG. *See* Dorsal root ganglion (DRG)

- Drugs, 90, 19, 21, 52, 70, 71, 77, 83, 87–86, 139, 148, 155, 162–164, 169–175, 222, 231, 245, 246, 258–261, 275–278, 311, 318, 321, 334, 355, 363, 365, 368, 369, 371, 379, 385, 389, 393, 417, 420, 430, 443, 444
- Dysesthesias, 69, 123, 125–126, 222, 225, 231
- E**
- Ego, 298–299, 310, 313, 418–420
- Emollient, 138–140, 185, 193, 236, 245, 268, 314, 317, 325, 346, 360
- Endocrine disorders, 267
- Ependymoma, 215, 226
- Epidemiology, 73–77, 200–201, 219, 225, 229, 230, 283–284
- Epidermal innervation, 132, 136–138, 222
- Epidermolysis bullosa acquisita (EBA), 193
- Excitability, 40, 44, 52, 380, 417
- Expectancy, 74–76, 93, 105, 161, 258, 284, 314
- Expectation, 18–19, 103–107, 117, 304
- Ex vivo, 51–52
- F**
- Functional, 6, 14, 22, 23, 25, 28, 33, 39, 40, 43, 52, 57, 58, 60–62, 118, 237, 295, 296, 301, 307–309, 321, 352, 365, 386, 417
- Functional MRI (fMRI), 21, 23, 25, 26, 28, 119, 120
- G**
- Gabapentin, 71, 212, 217, 222, 227, 238, 245, 247, 248, 259, 261, 276, 286, 348, 372, 379–386, 444
- Gastrin-releasing peptide (GRP), 55–90, 17–18, 33, 39, 50, 136, 137, 443–444
- Gate control, 71, 438
- Gender, 60, 73, 94, 117–120, 183, 383
- General population, 73, 111, 273, 290, 292, 304
- Genodermatoses, 82, 124, 313–316
- Glial, 335, 79, 50, 135, 215
- Glioma, 216, 316
- Glutamate, 55, 6, 90, 33, 137, 380
- GPCR. *See* G-protein coupled receptor (GPCR)
- G-protein coupled receptor (GPCR), 55, 14–18, 33, 359, 364
- Graves disease, 194, 268
- GRP. *See* Gastrin-releasing peptide (GRP)
- Guideline, 154, 155, 175, 227, 275, 286, 308, 318, 345–349, 443
- H**
- Hemangioma, 216, 226
- Hematologic malignancies, 175, 273, 430
- Hematology, 76, 82, 124, 161–163, 175, 242, 271–278, 283, 284, 296, 323, 393, 394, 440
- Hemodialysis, 76, 77, 241–244, 246–248, 290, 384, 385, 394, 430, 431
- Herpes, 89, 112, 125, 192, 230, 231, 320, 321, 330, 331, 334
- Herpes zoster infection, 230, 231
- Histamine, 335, 44, 14–18, 23–26, 28, 31–35, 39–43, 50, 51, 70, 88, 104, 118, 120, 131, 132, 134, 137, 147, 153, 157, 163, 164, 171–175, 184, 185, 193, 194, 211, 230, 243, 255, 256, 274, 291, 302, 303, 317, 318, 352, 353, 360, 361, 363–263, 368, 370, 371, 389, 400, 408, 426, 438–440
- HIV, 74, 76, 90, 124, 238, 352, 394, 418, 430, 432
- Hydroxyethyl starch, 77, 169, 170, 173–175, 253, 352, 390
- Hydroxyzine, 275, 325, 366, 369–372
- Hyperpigmentation, 159, 211, 221
- I**
- Ice-pack sign, 226
- Idiopathic Chronic Urticaria, 193–194
- IENFD. *See* Intraepidermal nerve fibre density (IENFD)
- IFSI classification, 123
- IL-33, 17, 19, 132, 138, 140, 163, 212, 275, 402, 427
- Immunomodulator, 185, 244, 247, 248, 355–356, 399, 443
- Immunosuppressants, 320, 338, 347, 397–403, 411, 426
- Incidence, 73, 76, 118, 119, 151, 169, 171–173, 175, 176, 201, 204, 229, 235, 242, 244, 247, 267, 271, 272, 278, 284, 339, 391, 431, 433
- Infections, 82, 124, 125, 151, 153, 154, 171, 197–205, 230, 231, 238, 254, 260, 267, 303, 304, 314, 317, 319–324, 329–335, 338, 339, 359
- Infestations, 197–205, 296, 314
- Inflammation, 79, 14, 49, 71, 123, 127, 132, 134, 147, 148, 200, 202, 212, 247, 310, 314, 334, 337, 346, 352, 355, 359, 361, 364, 400, 401, 408, 409, 427, 438
- Inhibitory control, 34, 43
- Intensity theory, 35
- Internal diseases, 87–89, 91, 285, 390, 432
- Intraepidermal nerve fibre density (IENFD), 57, 62, 63, 127, 235
- Intralesional glucocorticoid therapy, 230
- In vitro, 16, 33, 49–53, 136, 164, 211, 256, 369, 380, 401, 440, 444
- Irritant Contact Dermatitis, 145–148, 330
- Isolated pruritus, 203
- Itch, 335, 13, 21, 31, 39, 50, 57, 69, 73, 81, 85, 93, 97, 103, 111, 118, 123, 127, 131, 147, 151, 169, 183, 190, 203, 211, 215, 220, 225, 229, 236, 241, 253, 267, 272, 283, 289, 295, 301, 307, 314, 329, 346, 351, 355, 359, 363, 379, 389, 393, 397, 408, 415, 425, 437, 437
- Itch relief, 26, 401, 402
- Itchy skin, 23, 25–27, 35, 43, 89, 151, 215, 290, 314, 425–427
- J**
- Janus kinase inhibitors, 400–401

**K**

- Kappa receptor, 70, 245, 248, 390–391, 438  
 Keloid, 229, 230  
 Keratinocytes, 335, 55, 15, 16, 19, 49–51, 53, 127, 132, 134–137, 139, 140, 147, 174, 184, 191, 192, 212, 221, 316, 338, 356, 403, 407, 408, 426

**L**

- Lichen planus, 88, 124, 330, 331, 337, 356, 397–399  
 Lichen sclerosus, 330, 331, 335–337, 356, 372  
 Lichen simplex chronicus, 58, 82, 124, 125, 330, 331, 335  
 Life events, 292, 302, 305, 307, 308  
 Life quality, 93, 152, 190, 220, 290  
 Linear IgA Dermatitis, 193, 322–323  
 Liver, 17, 83, 88–90, 98, 160–162, 169, 170, 174, 242, 254–256, 258–262, 269, 285, 315, 323, 365, 368, 369  
 Localized pruritus, 87, 198, 216, 225, 230, 267, 269, 316, 334  
 Lupus erythematosus, 190  
 Lymphoma, 82, 87, 124, 176, 209–213, 271–278, 283, 284, 323, 390, 394, 398, 402, 409–410, 429–430  
 Lysophosphatidic acid (LPA), 17, 42, 132, 255, 257, 383

**M**

- Magnetic resonance imaging (MRI), 21, 22, 25, 226, 274, 438  
 Malignancy, 76, 89, 90, 161, 189, 211, 271–273, 275, 283–286, 339, 395  
 Malignant itch, 283–285  
 Mas-related G protein-coupled receptors (Mrgprs), 44, 90, 15–16, 19, 131, 134, 172  
 Mast cell, 44, 14, 17, 19, 49, 50, 53, 90, 127, 138, 151, 152, 157–165, 174, 175, 184, 193, 194, 210–212, 243, 256, 269, 272, 274, 275, 319, 320, 351, 356, 363–365, 400, 408, 426, 429, 430  
 Mast cell activation, 157, 161–163, 256  
 Mastocyte, 184  
 Mastocytosis, 124, 157–165, 319, 320, 372  
 Matrix metalloproteinases (MMPs), 136  
 Measurement of itch, 93–95, 97–100  
 Measurement of scratching, 97, 98, 100  
 Medical history, 88, 274, 332, 422  
 Mental, 23, 74, 94, 128, 190, 273, 290, 291, 295–298, 302, 308, 309, 314, 394, 416–419, 421  
 Menthol, 18, 245, 258, 346–348, 359–361  
 Methylene blue, 361  
 Microglia, 79, 139, 140  
 Microneurography, 43, 61, 62  
 Minocycline, 139  
 Mirtazapine, 185, 186, 212, 276–277, 286, 393–395  
 MMPs. *See* Matrix metalloproteinases (MMPs)  
 Model, 44, 55, 16, 18, 28, 35, 49–53, 131, 132, 134, 136, 138, 139, 148, 190, 268, 290, 302, 352, 361, 365, 380, 383, 384, 402, 408, 443

- Morphine, 105, 164, 172, 173, 246, 363, 384, 389–391  
 Motor-related regions, 23–26  
 Multiple Sclerosis (MS), 61, 62, 125, 194–195, 216  
 Mu receptor, 70, 390  
 Mycosis fungoides (MF), 209–212, 222, 272, 273, 275, 276, 409, 410, 429, 430  
 Myeloproliferative disorder, 272, 276

**N**

- Nalfurafine, 245–247, 257, 262, 390, 391  
 Naltrexone, 172–174, 241, 245, 246, 248, 257, 259, 260, 275, 277, 348, 390, 391  
 Narrow band ultraviolet B (NB-UVB), 185, 277, 425–433  
 Natriuretic peptide B (NPPB), 55–79, 137  
 NaV. *See* Sodium channels (NaV)  
 NB-UVB. *See* Narrow band ultraviolet B (NB-UVB)  
 Nerve, 335, 14, 21, 34, 40, 51, 57, 71, 81, 118, 127, 131, 147, 157, 162, 173, 184, 190, 211, 215, 221, 225, 230, 236, 261, 277, 310, 313, 346, 359, 364, 385, 389, 399, 407, 425, 432  
 Nerve conduction studies, 57, 58, 62, 63  
 Nerve growth factor (NGF), 18, 40, 41, 44, 51, 71, 133–140, 163, 184, 211, 230, 408  
 Neuralgia, 36, 61, 125, 230, 231, 334, 351, 352, 380, 383, 384  
 Neurogenic inflammation, 14, 49, 123, 127, 134, 352, 359, 408  
 Neurokinin-1 receptor (NK-1), 16, 137, 148, 162, 175, 227, 277, 407–412, 444  
 Neurokinin-1 receptor antagonist, 175  
 Neuron, 6, 25, 52, 60, 71, 246, 251  
 Neuropathic  
   component, 60, 384, 385  
   pain, 34, 36, 43, 60, 71, 127, 135, 139, 210, 222, 229, 236, 247, 352, 379, 380, 383–385, 407  
   pruritus, 60, 81, 127, 215–217, 223, 229–231, 236, 382, 383, 386, 409, 411  
   sensory dysfunction, 230  
 Neuropathy, 36, 58, 60–62, 71, 125, 127, 190, 219, 226, 230, 235–238, 268, 351, 352, 384, 386, 398, 399, 444  
 Neuropeptides, 44, 55, 79, 90, 14, 33, 40, 50, 71, 127, 131, 134, 137, 157, 162, 163, 184, 185, 222, 230, 277, 352, 356, 363, 380, 384, 407, 408, 426, 438, 443  
 Neurophysiology, 379  
 Neurotrophins, 40, 71, 127, 134, 139, 163, 184  
 NGF. *See* Nerve growth factor (NGF)  
 NK-1. *See* Neurokinin-1 receptor (NK-1)  
 NK-1R, 137  
 Nocebo, 71, 103–107  
 Nociceptive evoked potentials, 61–62  
 Nociceptive priming, 70, 71  
 Nociceptor, 44, 13, 14, 33–37, 39–43, 52, 69–71, 134, 222, 237, 430  
 Nocturnal scratching, 97–100  
 Notalgia paresthetica, 36, 60, 81, 87, 219–223, 382  
 NPPB. *See* Natriuretic peptide B (NPPB)

**O**

Objective, 44, 62, 93, 97, 99, 100, 115, 137, 258, 311, 353, 369, 391, 416, 418–420  
 Opioids, 79, 17, 26, 34, 52, 70, 88, 98, 131, 169, 231, 245, 255, 275, 286, 292, 310, 347, 363, 389, 431, 438  
 Osteoporosis, 162–164

**P**

PAG. *See* Periaqueductal gray (PAG)  
 Pain, 335, 14, 21, 31, 39, 57, 69, 94, 103, 113, 117, 127, 131, 146, 152, 162, 172, 191, 201, 210, 215, 219, 225, 230, 236, 247, 258, 273, 284, 303, 307, 314, 329, 351, 359, 395, 407, 417, 426, 431  
 Paraesthesias, 55, 71, 230  
 Parathyroid, 267–269, 439  
 Paresthesias, 58, 69, 205, 219, 225, 231, 236, 309, 351  
 Paroxetine, 170, 217, 231, 261, 277, 285, 286, 311, 394, 395, 412  
 Pathological scratching, 26  
 Pathophysiology of chronic itch, 21, 28  
 Patient benefit index (PBI), 112–115  
 Patient needs, 111–115  
 Patient-reported outcome (PRO), 93–95, 103, 111–112, 115, 289, 290  
 Patient reported outcomes, 93–95, 111–112, 289, 290  
 Pattern theory, 35, 36  
 PBI. *See* Patient benefit index (PBI)  
 Pemphigoid gestationes, 89, 124, 192–193  
 Pemphigus vulgaris, 191  
 Periaqueductal gray (PAG), 79  
 Personality, 104, 290–292, 297, 302, 304, 305, 419  
 Pharmacological MRI (phMRI), 21, 28  
 PhMRI. *See* Pharmacological MRI (phMRI)  
 Phosphodiesterase inhibitors, 401  
 Phototherapy, 148, 185, 212, 223, 245, 247, 248, 259, 262, 277, 317, 323, 348, 385, 425–433  
 Pimecrolimus, 148, 164, 338, 355, 356  
 Placebo, 26, 71, 103–107, 185, 245–247, 258, 260–262, 275, 286, 317, 353, 355, 370, 371, 381, 383, 385, 390, 391, 394, 400–402, 412, 427, 428, 431, 438–440  
 Pleasurability, 25, 26  
 Pregabalin, 71, 217, 238, 247, 248, 261, 276, 286, 348, 379–381, 383–386, 444  
 Prevalence, 73, 111, 117, 146, 151, 162, 190, 202, 210, 219, 225, 235, 241, 254, 271, 283, 304, 321, 329, 426  
 PRO. *See* Patient-reported outcome (PRO)  
 Prostaglandin D4, 66  
 Proteases, 16, 19, 50, 131, 157, 360  
 Pruriceptive afferent nerves, 225  
 Pruriceptors, 44, 13–19, 36, 39, 43, 52, 70, 71, 237, 307, 340  
 Prurigo, 74, 75, 82, 89, 94, 97, 124, 125, 210, 216, 222, 241, 255, 285, 291, 304, 314, 325, 352, 355, 382, 385, 386, 390, 391, 398, 399, 402, 408, 409, 411, 430–432, 443, 444

Prurigo nodularis, 82, 124, 192, 222, 241, 242, 255, 275, 291, 304, 352, 355, 382, 383, 385, 386, 390, 391, 398, 399, 402, 408, 409, 411–412, 430, 443, 444  
 Pruritus ani, 352, 355–356, 361  
 Pruritus elderly, 75, 433  
 Pruritus of undetermined origin (PUO), 77, 81, 382, 385, 430, 432–433, 443  
 Psoralen-ultraviolet A (PUVA), 138, 140, 164, 276, 277, 287, 410, 425–428, 430, 432, 433  
 Psoriasis, 42, 43, 75, 83, 87, 88, 94, 104, 107, 111–112, 114, 115, 124, 152, 183–186, 255, 290, 291, 297, 302, 304, 319, 330, 331, 335, 336, 352, 356, 360, 361, 390, 391, 399–402, 408, 418, 425, 429, 432, 433  
 Psyche, 295–299, 301, 313, 417–419  
 Psychic disorders, 303–305  
 Psychogenic, 57, 71, 82, 91, 124, 125, 291, 296, 303, 307–311, 394, 422  
 Psychological, 23, 69, 82, 83, 88, 106, 107, 111–114, 117, 119–120, 127, 162, 184, 289, 290, 295–299, 301, 302, 304, 307–311, 317, 379, 383, 393, 415–422  
 Psychological factors, 289–292, 307, 308, 383, 422  
 Psychosomatic aspects, 301–305  
 Psychotherapeutic approach, 305  
 Psychotherapy, 292, 296, 305, 417, 420  
 Psychotrope, 29–277, 308, 420  
 PUO. *See* Pruritus of undetermined origin (PUO)  
 PUVA. *See* Psoralen-ultraviolet A (PUVA)

**Q**

QoL. *See* Quality of life (QoL)  
 QST. *See* Quantitative sensory testing (QST)  
 Quality of life (QoL), 71, 77, 87, 88, 94–95, 97, 99, 111, 112, 120, 128, 131, 139, 146, 152–153, 175, 183, 190, 210, 212, 237, 254, 273, 289–291, 310, 316, 318, 319, 326, 371, 381–382, 399, 416, 429, 443  
 Quantitative sensory testing (QST), 57–60, 62, 63, 230, 236, 237

**R**

Raffinose, 361  
 Red man syndrome, 171  
 Renal failure, 25, 76, 83, 88, 255, 290, 430, 431  
 Reward system, 25

**S**

Salicylates, 170, 185, 361  
 Sarcoidosis, 61, 238, 254  
 Scabies, 83, 89, 90, 123, 124, 197–199, 203–204, 321, 333  
 Scar, 229, 230, 320, 323  
 Scratching, 55, 15, 23, 33, 44, 70, 87, 97, 104, 118, 124, 131, 146, 152, 158, 173, 192, 202, 219, 241, 254, 291, 296, 298  
 Scratch lesion, 62–63, 82, 87, 89, 91, 94, 119, 123–125, 225, 226, 285, 346–348

- Sema3A. *See* Semaphorin 3A (Sema3A)
- Semaphorin 3A (Sema3A), 40, 51, 133, 135–140
- Sensitive skin, 127–128
- Sensitization, 55, 15, 39–44, 70, 71, 88, 131, 132, 135, 136, 145, 147, 203, 225, 236, 310, 346, 352, 353, 356, 359, 379, 380, 383, 384, 386
- Sensory function, 40, 57–63, 308
- Sensory nerve fibers, 14, 132–134, 136, 139, 175, 226, 408, 426
- Serotonin reuptake inhibitors, 257
- Sertraline, 170, 257, 259, 261, 285, 311, 394, 395
- Sex, 117–120, 170, 229, 273, 319, 333, 422
- Sezary syndrome (SS), 209, 210, 276, 409
- Side effects, 26, 77, 87, 105, 106, 114, 120, 164, 165, 169, 171–173, 205, 248, 260, 321, 346–348, 352, 353, 361, 365, 367–370, 372, 383–386, 390, 394–395, 398, 409–411, 430, 458
- Sjögren's syndrome, 191
- Skin, 335, 14, 21, 31, 39, 49, 58, 69, 73, 81, 87, 97, 98, 104, 112, 118, 124, 128, 132, 146, 152, 158, 172, 184, 190, 197, 210, 220, 226, 230, 236, 242, 255, 268, 272, 284, 290, 296, 302, 308, 314, 330, 346, 352, 356, 361, 385, 389, 395, 398, 408, 416, 426, 432
- Skin diseases, 74–76, 88, 89, 98, 114, 131, 134, 145, 151, 152, 183, 186, 193, 197, 203, 236, 243, 267, 283–285, 290, 292, 296, 301, 302, 305, 314, 346, 355, 391, 395, 402, 416, 425, 427, 429, 430, 432, 433, 437
- Skin-ego, 298–299, 420
- Sleep, 93, 94, 97–100, 113, 175, 183, 190, 220, 248, 254, 262, 273, 285, 290, 301, 314, 348, 369, 380–382, 391, 394–395, 399, 418, 439
- Small-fibre neuropathies, 60–62
- Social learning, 103–105
- Sodium channels (NaV), 55, 90, 14, 15, 19, 39, 40, 42–44, 237
- Somatoform, 81, 83, 303, 304, 307–310, 394, 395
- Somatosensory cortex, 21–23, 70, 71
- Somatosensory evoked potentials, 57, 58, 61
- Somatosensory system, 57, 62
- SP. *See* Substance P (SP)
- Specificity, 24, 34, 36, 70, 297, 365, 403
- Spinal cord, 335–90, 14, 18, 26, 28, 34, 35, 37, 39, 43, 58, 70, 71, 135, 136, 139, 140, 195, 215–217, 226, 231, 246, 407, 444
- Spine, 222, 223, 226, 227, 237
- Squamous vulvar intraepithelial neoplasia, 338–339
- SS. *See* Sezary syndrome (SS)
- SSc. *See* Systemic sclerosis (SSc)
- Steroid, 169, 200, 203–205, 222, 260, 317, 320, 324–326, 346, 355–356, 418
- Stress, 74, 100, 118, 127, 151–153, 173, 184, 236, 237, 289, 292, 302–305, 308, 310, 314, 318, 332, 346, 347, 416, 418, 421
- Striatum, 22, 23, 25
- Strontium nitrate, 361
- Substance P (SP), 6, 90, 14, 16, 33, 51, 71, 127, 134, 135, 137, 148, 157, 162, 174, 175, 184–185, 230, 277, 352, 356, 380, 407–409, 411, 426, 427, 438
- Systemic sclerosis (SSc), 190–191, 195, 254
- Systemic therapy, 186, 277, 346–348, 403
- T**
- Tacrolimus, 51, 99, 148, 164, 193, 222, 244–246, 338, 355, 356, 382, 408
- Targeted cancer therapies, 175–176
- TDCS. *See* Transcranial Direct Current Stimulation (tDCS)
- Th2. *See* Type 2 helper T cell (Th2)
- Therapy, 62, 77, 94, 112, 120, 134, 153, 163, 170, 185, 190, 205, 226, 230, 238, 254, 277, 285, 317, 333, 346, 371, 382, 389, 397, 409, 416, 426, 434
- Thymic stromal lymphopoietin (TSLP), 17, 19, 39, 50–51, 132, 138, 140, 314, 315, 397, 402–403
- Thyroid, 90, 162, 176, 194, 267–269, 285
- Thyroid dysfunction, 194
- Topical therapy, 222, 238, 333, 334, 346, 349, 443, 444
- Transcranial Direct Current Stimulation (tDCS), 21, 26–28
- Transient receptor potential (TRP) ion channels, 14, 18, 41, 131, 134, 135, 359
- Treatment, 16, 28, 37, 51, 60, 70, 76, 85, 87, 94, 99, 104, 112, 128, 131, 146, 154, 163, 170, 185, 192, 198, 210, 217, 220, 227, 230, 237, 242, 257, 273, 285, 296, 304, 311, 314, 330, 346, 352, 356, 360, 368, 380, 390, 394, 397, 409, 416, 426, 439, 438
- Treatment goals, 111–115, 347
- Trigger factor, 85, 88, 132, 151, 153, 154, 163, 346
- TRP ion channels. *See* Transient receptor potential (TRP) ion channels
- TSLP. *See* Thymic stromal lymphopoietin (TSLP)
- Tumor, 124, 125, 135, 162, 164, 209, 215–217, 226, 272, 283, 286, 316, 338, 394, 408
- Type 2 helper T cell (Th2), 17, 132, 200, 210–212, 244, 275, 314, 316, 364, 400–402
- U**
- Ultraviolet A 1 (UVA1), 164, 213, 425, 427–430, 433
- Uraemic pruritus, 241–245, 268, 288
- Urea, 90, 347, 360, 398
- Uremic pruritus, 81, 87, 222, 244, 247, 257, 261, 352, 356, 360, 372, 381, 384, 385, 390, 391, 426, 431, 433, 439, 440, 444
- Urticaria, 16, 50, 83, 87, 88, 104, 112, 114, 124, 151–155, 158, 192–194, 200, 202, 205, 256, 268, 271, 290, 291, 297, 309, 314, 315, 317–320, 326, 370–372, 397–400, 428, 429
- Urticarial, 77, 152, 153, 192, 193, 198, 200, 205, 271, 318, 320, 322, 324, 426, 428
- UVA1. *See* Ultraviolet A 1 (UVA1)
- UV-based therapy, 138
- UV light exposure, 225, 226

**V**

Vanilloid, 40, 163, 351, 353  
Verbal suggestion, 103–107, 355  
Visual analog scale (VAS), 93, 120, 212, 222, 227, 382, 391, 440  
Visual analogue score (VAS), 152  
Voltage gated sodium channels, 55, 40, 42, 44  
Vulva, 331–333, 335, 337–339  
Vulvar intraepithelial neoplasia, 330, 331, 336–340  
Vulvar Paget's disease, 339

**W**

Wrist activity, 98–100

**Y**

Yeast infection, 330, 332

**Z**

Zoster, 112, 125, 230, 231, 321, 334, 351, 372